{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:48:09Z","timestamp":1792176489173,"version":"4.4.0"},"reference-count":36,"publisher":"American Academy of Pediatrics (AAP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND:<\/jats:title>\n                  <jats:p>Polysubstance use is common among opioid-using women, yet its association with pharmacotherapy for neonatal abstinence syndrome (NAS) remains unclear. We hypothesized that benzodiazepine exposure would increase risk of an infant developing pharmacologically treated NAS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS:<\/jats:title>\n                  <jats:p>We conducted a retrospective cohort study of maternal-infant dyads enrolled in Tennessee Medicaid, using individual-level data linkage of vital records and administrative (ie, outpatient, inpatient, and prescription) data from 2009 to 2011. These data underwent chart review from 2013 to 2016 to obtain clinically relevant exposure data (eg, toxicology testing). The association of antenatal exposures with pharmacologically treated NAS was evaluated by using multivariable logistic regression, controlling for maternal and infant factors and clustered by hospital.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>Among 112\u2009029 maternal-infant dyads, we confirmed 822 cases of NAS, of which 598 (72.7%) were cases of pharmacologically treated NAS. Infants who developed pharmacologically treated NAS were more likely to have been exposed to antenatal benzodiazepines compared with infants with confirmed NAS not treated pharmacologically (40.9% vs 30.8%; P = .008). In adjusted analyses, benzodiazepine exposure was associated with greater risk of developing pharmacologically treated NAS (odds ratio: 1.51; 95% confidence interval: 1.04\u20132.21). Alternatively, exposure to tobacco, marijuana, cocaine, gabapentin, and selective serotonin reuptake inhibitors were not associated with increased risk of developing pharmacologically treated NAS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>Among a population of infants with intrauterine polysubstance exposure, benzodiazepine exposure was an independent predictor of an infant developing pharmacologically treated NAS. Obtaining history of antenatal benzodiazepine exposure among opioid-exposed infants may allow for risk stratification and development of personalized care plans.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/hpeds.2018-0227","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T13:25:21Z","timestamp":1564665921000},"page":"569-575","source":"Crossref","is-referenced-by-count":54,"title":["Increased Severity of Neonatal Abstinence Syndrome Associated With Concomitant Antenatal Opioid and Benzodiazepine Exposure"],"prefix":"10.1542","volume":"9","author":[{"given":"Lauren A.","family":"Sanlorenzo","sequence":"first","affiliation":[{"name":"Departments of Pediatrics and"},{"name":"Mildred Stahlman Division of Neonatology and"},{"name":"Vanderbilt Center for Child Health Policy, Nashville, Tennessee; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William O.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and"},{"name":"Vanderbilt Center for Child Health Policy, Nashville, Tennessee; and"},{"name":"Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Dudley","sequence":"additional","affiliation":[{"name":"Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Stratton","sequence":"additional","affiliation":[{"name":"Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faouzi I.","family":"Maalouf","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, American University of Beirut, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Patrick","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and"},{"name":"Mildred Stahlman Division of Neonatology and"},{"name":"Vanderbilt Center for Child Health Policy, Nashville, Tennessee; and"},{"name":"Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"issue":"16","key":"2021120817095413800_B1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.15585\/mmwr.mm6516a2","article-title":"Opioid prescriptions among women of reproductive age enrolled in Medicaid - New York, 2008-2013","volume":"65","author":"Gallagher","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"2021120817095413800_B2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/AOG.0000000000000208","article-title":"Increase in prescription opioid use during pregnancy among Medicaid-enrolled women","volume":"123","author":"Desai","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"3","key":"2021120817095413800_B3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.whi.2017.03.001","article-title":"Nonmedical use of prescription opioids among pregnant U.S. women","volume":"27","author":"Kozhimannil","year":"2017","journal-title":"Womens Health Issues"},{"key":"2021120817095413800_B4","doi-asserted-by":"crossref","first-page":"F1000 Faculty Rev-887","DOI":"10.12688\/f1000research.7645.1","article-title":"Substance use during pregnancy","volume":"5","author":"Forray","year":"2016","journal-title":"F1000Res"},{"issue":"2","key":"2021120817095413800_B5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amepre.2016.02.014","article-title":"Trends in the concomitant prescribing of opioids and benzodiazepines, 2002-2014","volume":"51","author":"Hwang","year":"2016","journal-title":"Am J Prev Med"},{"issue":"8","key":"2021120817095413800_B6","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.2105\/AJPH.2017.303825","article-title":"Polysubstance use among US women of reproductive age who use opioids for nonmedical reasons","volume":"107","author":"Jarlenski","year":"2017","journal-title":"Am J Public Health"},{"issue":"10","key":"2021120817095413800_B7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/sj.jp.7211378","article-title":"Low birth weight and preterm births: etiologic fraction attributable to prenatal drug exposure","volume":"25","author":"Bada","year":"2005","journal-title":"J Perinatol"},{"issue":"1","key":"2021120817095413800_B8","doi-asserted-by":"crossref","first-page":"E80","DOI":"10.1111\/j.1440-1754.2012.02471.x","article-title":"Profile of infants born to drug-using mothers: a state-wide audit","volume":"49","author":"Abdel-Latif","year":"2013","journal-title":"J Paediatr Child Health"},{"key":"2021120817095413800_B9","doi-asserted-by":"crossref","first-page":"906723","DOI":"10.1155\/2014\/906723","article-title":"Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States","volume":"2014","author":"Whiteman","year":"2014","journal-title":"J Pregnancy"},{"issue":"2","key":"2021120817095413800_B10","article-title":"Neonatal drug withdrawal [published correction appears in Pediatrics. 2014;133(5):937]","volume":"129","author":"Hudak","year":"2012","journal-title":"Pediatrics"},{"key":"2021120817095413800_B11","article-title":"A collaborative approach to the treatment of pregnant women with opioid use disorders. HHS publication No. 16-4978. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2016","author":"Substance Abuse and Mental Health Services Administration"},{"issue":"8","key":"2021120817095413800_B12","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/jp.2015.36","article-title":"Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012 [published correction appears in J Perinatol. 2015;35(8):667]","volume":"35","author":"Patrick","year":"2015","journal-title":"J Perinatol"},{"issue":"22","key":"2021120817095413800_B13","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1056\/NEJMsa1500439","article-title":"Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs","volume":"372","author":"Tolia","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"2021120817095413800_B14","doi-asserted-by":"crossref","first-page":"e20173520","DOI":"10.1542\/peds.2017-3520","article-title":"Incidence and costs of neonatal abstinence syndrome among infants with Medicaid: 2004-2014","volume":"141","author":"Winkelman","year":"2018","journal-title":"Pediatrics"},{"issue":"25","key":"2021120817095413800_B15","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1056\/NEJMra1600879","article-title":"Neonatal abstinence syndrome","volume":"375","author":"McQueen","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2021120817095413800_B16","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1542\/peds.2014-3299","article-title":"Prescription opioid epidemic and infant outcomes","volume":"135","author":"Patrick","year":"2015","journal-title":"Pediatrics"},{"issue":"4","key":"2021120817095413800_B17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/ADM.0000000000000207","article-title":"Neonatal abstinence syndrome: presentation and treatment considerations","volume":"10","author":"Kaltenbach","year":"2016","journal-title":"J Addict Med"},{"key":"2021120817095413800_B18","doi-asserted-by":"crossref","first-page":"j3326","DOI":"10.1136\/bmj.j3326","article-title":"Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study","volume":"358","author":"Huybrechts","year":"2017","journal-title":"BMJ"},{"issue":"8","key":"2021120817095413800_B19","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/j.1360-0443.2012.03844.x","article-title":"Methadone and perinatal outcomes: a prospective cohort study","volume":"107","author":"Cleary","year":"2012","journal-title":"Addiction"},{"issue":"1","key":"2021120817095413800_B20","doi-asserted-by":"crossref","first-page":"e20174183","DOI":"10.1542\/peds.2017-4183","article-title":"Positive predictive value of administrative data for neonatal abstinence syndrome","volume":"143","author":"Maalouf","year":"2019","journal-title":"Pediatrics"},{"issue":"6","key":"2021120817095413800_B21","first-page":"312","article-title":"Early treatment innovation for opioid-dependent newborns: a retrospective comparison of outcomes, utilization, quality, and safety, 2006-2014","volume":"44","author":"Summey","year":"2018","journal-title":"Jt Comm J Qual Patient Saf"},{"issue":"10","key":"2021120817095413800_B22","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/cid\/ciu643","article-title":"Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012","volume":"59","author":"Suryaprasad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2021120817095413800_B23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.drugpo.2017.05.027","article-title":"High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: assessing barriers to hepatitis C prevention","volume":"47","author":"Puzhko","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"1\u20133","key":"2021120817095413800_B24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pain.2005.09.020","article-title":"Regular use of prescribed opioids: association with common psychiatric disorders","volume":"119","author":"Sullivan","year":"2005","journal-title":"Pain"},{"issue":"6","key":"2021120817095413800_B25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1542\/hpeds.2016-0218","article-title":"Male sex associated with increased risk of neonatal abstinence syndrome","volume":"7","author":"Charles","year":"2017","journal-title":"Hosp Pediatr"},{"key":"2021120817095413800_B26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1360-0443.2012.04038.x","article-title":"Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication","volume":"107","author":"Kaltenbach","year":"2012","journal-title":"Addiction"},{"issue":"5","key":"2021120817095413800_B27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.pediatrneurol.2015.06.023","article-title":"Neonatal gabapentin withdrawal syndrome","volume":"53","author":"Carrasco","year":"2015","journal-title":"Pediatr Neurol"},{"issue":"4","key":"2021120817095413800_B28","doi-asserted-by":"crossref","first-page":"396.e1","DOI":"10.1016\/j.ajog.2008.06.088","article-title":"Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates","volume":"199","author":"Seligman","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"2021120817095413800_B29","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1471-0528.2008.02073.x","article-title":"Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources","volume":"116","author":"Dryden","year":"2009","journal-title":"BJOG"},{"issue":"11","key":"2021120817095413800_B30","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/j.1360-0443.1994.tb03743.x","article-title":"The benzodiazepine withdrawal syndrome","volume":"89","author":"P\u00e9tursson","year":"1994","journal-title":"Addiction"},{"issue":"8","key":"2021120817095413800_B31","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/s00134-007-0696-x","article-title":"Withdrawal symptoms in children after long-term administration of sedatives and\/or analgesics: a literature review. \u201cAssessment remains troublesome\u201d","volume":"33","author":"Ista","year":"2007","journal-title":"Intensive Care Med"},{"key":"2021120817095413800_B32","doi-asserted-by":"crossref","first-page":"j760","DOI":"10.1136\/bmj.j760","article-title":"Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis","volume":"356","author":"Sun","year":"2017","journal-title":"BMJ"},{"key":"2021120817095413800_B33","doi-asserted-by":"crossref","first-page":"h2698","DOI":"10.1136\/bmj.h2698","article-title":"Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study","volume":"350","author":"Park","year":"2015","journal-title":"BMJ"},{"issue":"1","key":"2021120817095413800_B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC guideline for prescribing opioids for chronic pain - United States, 2016","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"2021120817095413800_B35","unstructured":"US Food and Drug Administration. FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use. 2016. Available at: https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm518697.htm. Accessed August 31, 2016"},{"key":"2021120817095413800_B36","doi-asserted-by":"crossref","first-page":"h2102","DOI":"10.1136\/bmj.h2102","article-title":"Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study","volume":"350","author":"Desai","year":"2015","journal-title":"BMJ"}],"container-title":["Hospital Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article-pdf\/9\/8\/569\/815827\/hpeds_2018-0227.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article-pdf\/9\/8\/569\/815827\/hpeds_2018-0227.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T17:26:45Z","timestamp":1638984405000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article\/9\/8\/569\/26808\/Increased-Severity-of-Neonatal-Abstinence-Syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,1]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/hpeds.2018-0227","relation":{},"ISSN":["2154-1663","2154-1671"],"issn-type":[{"value":"2154-1663","type":"print"},{"value":"2154-1671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,1]]}}}